Results 151 to 160 of about 997,609 (339)

Effects of sodium–glucose co‐transporter inhibitors on individual clinical endpoints and quality of life

ESC Heart Failure, Volume 12, Issue 2, Page 1271-1282, April 2025.
Effects of SGLTi on Individual Clinical Endpoints and Quality‐of‐Life: outcome from randomized data. Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLTis) have cardiovascular protective effects. We aimed to assess the effects of SGLTis on individual hard clinical endpoints and quality of life (QoL) in patients with cardiovascular risk factors.
Jia Liao, Yang Chen, Zhiyu Ling, Helmut Pürerfellner, Martin Martinek, Michael Derndorfer, Johannes Niel, Ramin Ebrahimi, Matthias Heukäufer, Sarah Janschel, Davide Di Vece, Klaus Empen, Astrid Hummel, Bishwas Chamling, Piotr Futyma, Fahim Ebrahimi, Márcio G. Kiuchi, Shaowen Liu, Yuehui Yin, Alexandra Schratter, Willem‐Jan Acou, Philipp Sommer, Boris Schmidt, Julian K. R. Chun, Christian Meyer, Marcus Dörr, Christian Templin, Shaojie Chen   +27 more
wiley   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Unannounced telephone pill counts for assessing varenicline adherence in a pilot clinical trial

Patient Preference and Adherence, 2011
Nia Thompson1, Niaman Nazir1, Lisa Sanderson Cox1,2, Babalola Faseru1,2, Kathy Goggin3, Jasjit S Ahluwalia4, Nicole L Nollen1,21University of Kansas School of Medicine, Department of Preventive Medicine and Public Health, Kansas City, KS, USA ...
Thompson N, Nazir N, Sanderson Cox L, Faseru B, Goggin K, Ahluwalia JS, Nollen NL   +6 more
doaj  

Community banking : is the playing field changing for bankers and supervisors? [PDF]

Excerpt from a speech delivered by Federal Reserve Bank of Kansas City President Thomas M.
Thomas M. Hoenig
core  

FDG PET/CT imaging and circulating biomarkers of inflammation in desmoplakin cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1485-1489, April 2025.
Abstract Aims Inflammation has been implicated in the pathogenesis of desmoplakin (DSP) cardiomyopathy, and retrospective studies have described abnormal myocardial fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) findings in symptomatic patients eventually diagnosed with DSP cardiomyopathy.
Sanjay Divakaran, Vinay Randhawa, Usman A. Tahir, Matthew Robertson, Anam A. Waheed, Anna Perillo, Leanne Barrett, Ron Blankstein, Mark W. Feinberg, Marcelo F. Di Carli, Neal K. Lakdawala   +10 more
wiley   +1 more source

Retrospective Study on the Efficacy and Safety of Dulaglutide in Patients with Diabetes and Moderate-Advanced Chronic Kidney Disease

International Journal of Nephrology and Renovascular Disease
Sriya Kosaraju,1 Rong M Zhang2 1Department of Biomedical Sciences, University of Missouri-Kansas City, Kansas City, MO, USA; 2Department of Medicine-Division of Endocrinology, Washington University, St Louis, MO, USACorrespondence: Rong M Zhang, Email ...
Kosaraju S, Zhang RM
doaj  

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

NON-PARAMETRIC AND SEMI-PARAMETRIC TECHNIQUES FOR MODELING AND SIMULATING CORRELATED, NON-NORMAL PRICE AND YIELD DISTRIBUTIONS: APPLICATIONS TO RISK ANALYSIS IN KANSAS AGRICULTURE [PDF]

Parametric, non-parametric, and semi-parametric approaches are commonly used for modeling correlated distributions. Semi-parametric and non-parametric approaches are used to examine the risk situation for Kansas agriculture.
Featherstone, Allen M., Kastens, Terry L.   +1 more
core   +1 more source

Clinician Practices in Determining Expected Body Weights Across Eating Disorders: A Mixed Methods Study

European Eating Disorders Review, EarlyView.
ABSTRACT Objective Eating disorder (ED) treatment often involves establishing expected body weights (EBWs). While individualised approaches are commonly used, whether and how EBWs are set across EDs, clinician perspectives on different approaches, and clinician training in this practice remain poorly understood.
Agatha A. Laboe, Molly F. Steinhoff, Siena S. Vendlinski, Anna Kreynin, Sarah Johnson‐Munguia, Ava Heyrman, Sophia Kreckler, Caitlyn Ruud, Katherine Schaumberg   +8 more
wiley   +1 more source

Combination Hyaluronic Acid and Multipotent Stromal Cells Fails to Improve Rat Knee OA Outcomes Compared to Cells Alone

Orthopedic Research and Reviews
Kennedy Michele Davis,1 Megan Hamilton,2 Donald Muathe,2 Aldyn Wildey,2 Stephen Harrington,2 Douglas C Bittel,1 Michael Filla,1 Lisa Stehno-Bittel2,3 1College of Biosciences, Kansas City University, Kansas City, MO, USA; 2Likarda, Inc, Kansas City, MO ...
Davis KM, Hamilton M, Muathe D, Wildey A, Harrington S, Bittel DC, Filla M, Stehno-Bittel L   +7 more
doaj